451 results about "Ischemic stroke" patented technology

The invention provides a medicine for preventing and treating cerebral arterial thrombosis, and belongs to the technical field of neuromedicine. The medicine comprises salmon polypeptide as shown in SEQ ID NO.1 and a pharmaceutically acceptable carrier, and experimental results show that the salmon polypeptide has good safety, can effectively improve oxygen-glucose deprivation / reoxygenation injury of brain cells, and remarkably reduces neurological impairment and cerebral infarction of mice suffering from cerebral arterial thrombosis. The invention also discloses a pharmaceutical composition for treating cerebral arterial thrombosis. The pharmaceutical composition comprises the salmon polypeptide and edaravone. The composition shows a remarkable synergistic effect, compared with the single use of the salmon polypeptide or edaravone, the composition can more remarkably reduce neurological impairment and cerebral infarction, and the actual effect is obviously superior to the theoretical superposition effect. Therefore, the invention provides a novel and more effective treatment scheme for the treatment of cerebral arterial thrombosis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention belongs to the technical field of medical imaging, and particularly relates to an ischemic stroke image segmentation method based on a wavelet pooling neural network, and the method comprises the following steps: firstly, employing a U-Net convolutional neural network as a basic network architecture, and adding a convolution residual module and a convolution residual in each convolution block of a coding path; inputting the preprocessed feature map into a convolution block of a coding path; then obtaining a first preliminary effective feature layer, and carrying out lossless sampling through a wavelet pooling module; a channel attention SE module is connected behind the wavelet pooling layer, and channel feature redirection is carried out through extrusion, excitation and re-calibration; after each down-sampling operation, inputting the feature map into a pyramid expansion coordinate attention module, and realizing multi-scale feature fusion through cavity convolution and coordinate attention; and then in a decoding path, after each up-sampling operation, inputting the feature map into a space attention module, and finally outputting a segmentation result. The segmentation result output by the method is more accurate.

The invention relates to a zero-exchange balloon catheter stent system with a far-end protective umbrella and a using method, and belongs to the technical field of medical instruments. Comprising a balloon catheter and a stent system which are connected, the stent system comprises a conveying system and a stent; the conveying system comprises a control core wire; the center of the control core wire is provided with a connecting binding wire fixing hole and a connecting binding wire releasing point; the support comprises a near-end support, a connecting area and a far-end protective umbrella, and the connecting area is located between the near-end support and the far-end protective umbrella; the connecting area comprises a connecting binding wire, a protective umbrella wire binding ring and a protective umbrella connecting wire. The far-end protection umbrella and the near-end support are designed to be a separable combination, instrument exchange is not needed in the operation process, the operation process is simplified, the operation difficulty is reduced, the operation time is shortened, and therefore the risk of complications such as ischemic stroke is reduced.

The invention provides an interpretable ML method and system for predicting the death risk of an ICU stroke patient in a hospital, and belongs to the technical field of medical care informatics and electric digital data processing. The ICU cerebral arterial thrombosis patient in-hospital death risk prediction method comprises the steps of S1, inputting variables, related to the in-hospital death risk of the ICU cerebral arterial thrombosis patient, of a current patient; s2, performing in-hospital death risk prediction on the current patient by adopting a pre-constructed optimal prediction model for the in-hospital death risk of the ICU cerebral arterial thrombosis patient to obtain an in-hospital death prediction probability; and S3, performing explanatory analysis on the optimal prediction model by using an SHAP method, and analyzing the importance of variables to a hospital death risk prediction result. According to the method, the hospital death risk of the ICU cerebral arterial thrombosis patient can be quickly and accurately predicted, and an explanatory analysis can be provided for the prediction result, so that a clinical decision is guided.

APRIL research shows that in a selected stroke patient, infusion of 0.2 mg / kg of ApTOLL (SEQ ID NO: 1) in combination with intravascular treatment is safe, and the death rate of 90 days is reduced. ApTOLL has proved to limit intracranial hemorrhage and reperfusion injury which may occur after recanalization, and also improve early nerve injury and long-term disability. ApTOLL molecules are provided for reducing the risk of intracranial or secondary bleeding after acute ischemic stroke, reducing nerve injury, and improving nerve recovery in a subject.

The invention provides a multi-modal cerebral arterial thrombosis medical image segmentation method, device and equipment, and the method comprises the steps: extracting the independent features of different modal medical images through combining a ViT encoder branch and a CNN encoder branch which are finely adjusted by a hybrid expert as a multi-modal image double-branch coding network; further integrating complementary information of different modes by using a mode missing adaptive fusion network, and performing global-local information interaction between CNN features and ViT features by using an encoder branch interaction network, so that specific features and cross-mode invariant features of different available modes can be decoupled under the condition of mode missing; and meanwhile, the advantages of different types of features are fully utilized, and the value information of the multi-modal image features is deeply mined, so that accurate multi-modal cerebral arterial thrombosis medical image segmentation and imaging are realized, and the method is high in reliability, good in accuracy and good in practicability.

The invention relates to a traditional Chinese medicine composition for treating ischemic stroke and a method and application thereof, and belongs to the technical field of traditional Chinese medicines. The invention discloses a traditional Chinese medicine composition for treating ischemic stroke. The traditional Chinese medicine composition is prepared from the following raw materials: ginseng, pseudo-ginseng, radix polygoni multiflori preparata, ligusticum wallichii, safflower carthamus, salvia miltiorrhiza, hawthorn, loranthus parasiticus, longspur epimedium, radix puerariae, cornu bubali, ginseng leaves, rhizoma acori graminei and borneol. According to the preparation method disclosed by the invention, the ligusticum wallichii and compound bacteria consisting of lactobacillus plantarum, bacillus subtilis and coriolus hirsutus are fermented, so that more laccase and active substances are generated in a fermented product, and then the fermented product is subjected to compound enzyme treatment, so that the processed ligusticum wallichii is better in medicine effect, and the curative effect of the ligusticum wallichii is improved. Therefore, the treatment effect of the traditional Chinese medicine composition for treating ischemic stroke is enhanced, neurological dysfunction caused by cerebral ischemia can be remarkably relieved, and the traditional Chinese medicine composition has a good protection effect on ischemic stroke nerve injury.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The invention discloses a potential stroke risk assessment method and system after coronary artery recanalization, and the method comprises the steps: obtaining the heart and cerebral vessel image data of a patient, and constructing a complete heart and cerebral artery blood vessel geometric model; based on the cardio-cerebral artery blood vessel geometric model, numerical simulation is conducted on the flowing conditions of blood flow in coronary arteries and cerebral vessels by means of a computational fluid mechanics method, and the pressure ratio before and after coronary artery stenosis and the partial pressure ratio of the cerebral vessels are calculated; according to the pressure ratio and the partial pressure ratio, the potential risk of the cerebral arterial thrombosis is quantitatively evaluated, and a cerebral blood flow partial pressure ratio numerical value and a cerebral arterial thrombosis risk evaluation report are generated. According to the cerebral apoplexy risk quantitative evaluation method, by integrating coronary artery CTA and cranial CTA or MRA data, reconstructing a complete heart and cerebral vessel geometric model and simulating heart and cerebral blood flow changes before and after a coronary artery recanalization operation, and particularly by calculating coronary artery FFR and cerebral blood flow partial pressure ratio FPR, an evaluation report is generated, and a basis for quantitative evaluation of the cerebral apoplexy risk in the operation is provided for clinical doctors.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

Described herein are compounds and methods of treating or imaging a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of a cromolyn ester.

The invention discloses a nasal delivery multistage targeting bionic nano drug delivery system as well as a preparation method and application of the nasal delivery multistage targeting bionic nano drug delivery system. According to the drug delivery system, a black phosphorus nanosheet with an active oxygen scavenging effect is used as an inner core carrier, a neuroprotective agent fingolimod hydrochloride FTY720 and polydimethyldiguanide PolyMet are loaded, and a microcolloid cell membrane and a mitochondrial membrane are modified on the surface of the preparation; the nano drug delivery system is applied to treatment of cerebral arterial thrombosis reperfusion injury, can overcome the blood brain barrier, can quickly enter the brain through nasal administration, realizes efficient delivery of drugs, remarkably reduces the cerebral infarction area, reduces the brain inflammation level, protects nerve cells, greatly relieves cerebral arterial thrombosis reperfusion injury, and has application prospects.

Methods and devices are disclosed that enable safe, rapid and relatively short and straight access to the cerebral arteries for the introduction of interventional devices to treat acute ischemic stroke. In addition, the disclosed methods and devices provide means to securely close the access site to the cerebral arteries to avoid the potentially devastating consequences of a transcervical hematoma.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to N-methylation modified cyclopeptide and application thereof. On the basis of a GluA2-3Y polypeptide sequence, chemical modification and transformation of amido bond N-methylation and head-tail cyclization are carried out, the N-methylation modified cyclopeptide with stable metabolism and good permeability is obtained, and the endocytosis of a GluA2AMPA receptor is blocked to protect nerve cells, so that the GluA2AMPA receptor can be effectively inhibited, and the GluA2AMPA receptor can be effectively inhibited. The invention also provides application of the cyclic peptide in preparation of drugs for treating cerebral arterial thrombosis.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention discloses application of (20S)-ginsenoside Rh1 in preparation of drugs for preventing and / or improving cerebral arterial thrombosis, and relates to the technical field of medical application of natural drugs. The invention verifies that (20S)-ginsenoside Rh1 up-regulates the expression of an anti-apoptosis gene by promoting STAT3 phosphorylation and translocation to a cell nucleus, so that the (20S)-ginsenoside Rh1 plays a role in protecting neuronal injury induced by sugar oxygen deprivation. In MCAO model mice, the (20S)-ginsenoside Rh1 obviously relieves the symptom of ischemic cerebral apoplexy and has positive influence on neurodegenerative events related to cerebral infarction, and the anti-apoptosis and neuroprotection effects are most prominent. Mechanism research shows that (20S)-ginsenoside Rh1 plays a therapeutic role in PC12 cell and MCAO model mice by activating a JAK2 / STAT3 signal channel.

The invention belongs to the field of medical image processing, and provides a thrombus composition visual navigation method based on a CT image, which comprises the following steps: step 1, evaluating the CT image, and sketching thrombus according to the CT image of a stroke patient; 2, feature selection and model construction, wherein thrombus is divided into different areas; 3, performing histological evaluation, and associating different regions with tissue components; 4, outputting to a user: extracting the characteristics of each region to predict the prognosis of the patient; and fusing the CTA image and the DSA image, performing thrombus extraction navigation, and automatically and visually presenting different regions of thrombus components. The invention provides a visualization method for helping doctors to evaluate thrombus components of ischemic stroke patients.

The invention provides an extract extracted from rhodiola rosea and used for preventing and treating cerebral arterial thrombosis, which is prepared by the following steps: obtaining a dry rhodiola rosea raw material, and crushing the raw material; performing extraction treatment on the crushed raw materials by adopting an ethanol solution to obtain an extracting solution; carrying out concentration treatment on the extracting solution to obtain an extract; dissolving the extract in water, and carrying out separation treatment to obtain supernate; adjusting the pH value of the supernate; carrying out adsorption and purification treatment on the supernatant with the adjusted pH value to obtain an eluent; and concentrating and drying the eluent to obtain the extract.

The present invention discloses a nano-thermosensitive assembled gel for nasal administration, a preparation method thereof and its use, namely, mitochondrion-targeted puerarin nanoparticles, a thermosensitive gel, a preparation method thereof and its use. The nano-thermosensitive assembled gel for nasal administration of the present invention uses chitosan modified with SS-31 peptide having mitochondrion-targeting and transmembrane properties as a carrier material, and uses a thioketal cross-linking agent sensitive to reactive oxygen species (ROS) to cross-link the modified chitosan to prepare nanoparticles loaded with puerarin. Through a poloxamer thermosensitive gel system, a thermosensitive nanogel drug reservoir encapsulating the nanoparticles is constructed, and its application in the preparation of drugs for treating nervous system diseases realizes the targeting of the drug to the mitochondria of cerebral ischemic stroke injury, responsive cleavage in an environment rich in ROS, release of the drug, increase of the drug concentration in the mitochondria, and improvement of the brain bioavailability of puerarin, providing a more suitable and effective new dosage form for the treatment of stroke.

Clot engagement element comprising bundle of unwoven fibers can be assembled to form an acute stroke treatment device. The device has the capability of forming a three dimensional filtration matrix comprising effective pores with a distribution of sizes. The bundle of fiber design allows the device to be effectively delivered into circuitous cerebral arteries to remove clot that causes stroke. The fiber bundle based filtration matrix offers the advantages of conforming to the changing inner perimeter of a blood vessel during a clot removal process and thus the capability to effectively retain and remove a clot in the vessel. The filtration matrix offers the additional advantage to trap any break-off of the clot during the removal process. A plurality of fiber bundles can be combined to form an effective clot engagement element. Supplemental engagement structure as well as mechanical treatment structure can be integrated into the stroke treatment device. The deployment of the fiber based elements can be facilitated by actuation tool. Aspiration can be employed during the clot removal process.

The invention discloses an application of a hypoxia pretreated extracellular vesicle / miR-27b-3p in the treatment of ischemic stroke. The research proves that both the neuron-derived EV and H-EV can promote in-vivo and in-vitro MCAO repair. The two vesicles secreted by neuronal cells can significantly influence phenotypic change and apoptosis of astrocytes, wherein the effect of H-EV is more obvious than that of EV. Besides, the research result shows that H-EV secreted by neurons can regulate a PI3K / AKT signal channel by transmitting miR-27b-3p, so that astrocytes are promoted to be converted from the A1 phenotype to the A2 phenotype. The research of the invention provides a new therapeutic target and strategy for treating ischemic stroke.

A use of water-soluble tomato concentrate in the preparation of a drug for preventing or treating cerebral ischemia-reperfusion injury or in the preparation of a composition for preventing or treating cerebral ischemia-reperfusion injury. After long-term research, on the basis of neurological function evaluation, tetrazolium red staining and HE staining, the researchers first found and proved that water-soluble tomato concentrate has a significant repair effect on ischemic stroke reperfusion injury, can significantly reduce the cerebral infarction area, lower the neurological deficits score and improve the brain tissue pathology, and can be applied to the preparation of a composition for preventing or treating cerebral ischemia-reperfusion injury.

Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.

A balloon expandable stent having multiple rings and cells with ultra-thin struts, wherein the sizes of the cells are larger proximally and varies amongst the rings, enabling the stent to expand to a larger diameter at its proximal end compared with the distal end. A conical shape rather than the classic cylindrical design post deployment ensures adequate opposition of the stent to the arterial wall and avoids supramaximal expansion at the distal end. A unique monorail angioplasty balloon catheter delivers the stent through tortuous intracranial arteries with longer working length. A longer segment with traversing microwire enables modification in stiffness depending on stiffness of microwire, and reduction in length of segment with a hypotube alone.

The invention provides an application of combination of indobufen and butylphthalide in preparation of a drug for preventing and / or treating cerebrovascular diseases, indobufen and butylphthalide are combined for use, have a synergistic effect, remarkably improve the treatment effect, can be used for preparing the drug for preventing, secondarily preventing or treating the cerebrovascular diseases, and has a wide application prospect. The medicine is especially suitable for treating cerebral apoplexy and transient ischemic attack, and can be used for prophylactically improving cerebral infarction caused by cerebral arterial thrombosis.

The invention discloses an application of baricitinib in treatment of cerebral arterial thrombosis, and the baricitinib is used as a neuroprotective agent and is applied to treatment of cerebral arterial thrombosis after large vascular occlusion. The application of the invention reduces neuroinflammatory response, reduces nerve injury, protects nerves, improves stroke prognosis, and improves treatment effect.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

The invention discloses application of eugenin in preparation of a medicine for treating cerebral arterial thrombosis, and belongs to the technical field of medicines. An in-vivo middle cerebral artery occlusion model is adopted, after reperfusion is conducted for 24 h, the cerebral infarction volume and movement coordination function defect of a mouse are detected to evaluate the treatment effect of eugenin, and activation of microglial cells and survival of neuronal cells are observed through immunofluorescence to clarify the action way of eugenin. Pharmacological activity shows that eugenin can obviously reduce the cerebral infarction volume of a model mouse, improve pathological damage of cells and promote recovery of a motion coordination function, and the action way of eugenin is to promote survival of neuronal cells and inhibit activation of microglial cells. Research results indicate that eugenin has the effect of resisting cerebral arterial thrombosis and can be used as a candidate medicine for developing the cerebral arterial thrombosis resisting medicine.

A glycoside drug oral preparation for treating cerebral ischemic stroke during the recovery period and a preparation method therefor. The glycoside drug is (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-(4-methoxyphenyl)butoxy)tetrahydro-2H-pyran-3,4,5-triol. The oral preparation can provide a high drug loading capacity, release the drug within a short time period, and ensure rapid drug dissolution, and the prepared tablet has high stability, involves a simple preparation process and is suitable for large-scale industrial production.